Cardiff Oncology Inc expected to post a loss of 23 cents a share - Earnings Preview

Cardiff Oncology

01/05/2023 13:18

* Cardiff Oncology Inc  CRDF.OQ   CRDF.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 3
(estimated). 
    * The San Diego California-based  company is expected to
report  a
24.9% decrease in revenue to $55.6 thousand from $74 thousand a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Cardiff Oncology
Inc is
for a loss of 23 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cardiff
Oncology
Inc is $5​, above​ its last closing price of $1.74. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.22       -0.23      -0.20     Beat    14.9
 Sep. 30 2022  -0.27       -0.26      -0.20     Beat    24.2
 Jun. 30 2022  -0.26       -0.25      -0.24     Beat    4.8​
 Mar. 31 2022  -0.25       -0.23      -0.25     Missed  -8.2
 ​​Dec.        -0.17       -0.17      -0.23     Missed  -34
 31 2021                                                
 Sep. 30 2021  -0.17       -0.17      -0.17     Met     0​
 Jun. 30 2021  -0.15       -0.15      -0.17     Missed  -13.5
 Mar. 31 2021  -0.16       -0.15      -0.14     Beat    5.1
 This summary was machine generated May 1 at 12:18 GMT.  All
figures in US dollars  unless otherwise stated